JP2023522198A5 - - Google Patents

Info

Publication number
JP2023522198A5
JP2023522198A5 JP2022562788A JP2022562788A JP2023522198A5 JP 2023522198 A5 JP2023522198 A5 JP 2023522198A5 JP 2022562788 A JP2022562788 A JP 2022562788A JP 2022562788 A JP2022562788 A JP 2022562788A JP 2023522198 A5 JP2023522198 A5 JP 2023522198A5
Authority
JP
Japan
Prior art keywords
seq
fusion protein
antigenic polypeptides
immunogenic
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522198A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028029 external-priority patent/WO2021212123A1/en
Publication of JP2023522198A publication Critical patent/JP2023522198A/ja
Publication of JP2023522198A5 publication Critical patent/JP2023522198A5/ja
Pending legal-status Critical Current

Links

JP2022562788A 2020-04-17 2021-04-19 黒色腫を治療するためのｃｔｌ抗原の融合タンパク質 Pending JP2023522198A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20170174.5 2020-04-17
EP20170174 2020-04-17
PCT/US2021/028029 WO2021212123A1 (en) 2020-04-17 2021-04-19 Fusion proteins of ctl antigens for treating melanoma

Publications (2)

Publication Number Publication Date
JP2023522198A JP2023522198A (ja) 2023-05-29
JP2023522198A5 true JP2023522198A5 (enExample) 2024-05-20

Family

ID=70295067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562788A Pending JP2023522198A (ja) 2020-04-17 2021-04-19 黒色腫を治療するためのｃｔｌ抗原の融合タンパク質

Country Status (6)

Country Link
US (1) US20230167163A1 (enExample)
EP (1) EP4136097A1 (enExample)
JP (1) JP2023522198A (enExample)
CN (1) CN116057067A (enExample)
CA (1) CA3179694A1 (enExample)
WO (1) WO2021212123A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020309202A1 (en) * 2019-07-05 2021-12-09 Enara Bio Limited Novel cancer antigens and methods
JP2023522193A (ja) * 2020-04-17 2023-05-29 ザ フランシス クリック インスティチュート リミティッド 抗原プール
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298364B6 (cs) * 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
HUP0203035A3 (en) * 1998-07-14 2007-12-28 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
DK1871391T3 (da) 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
AT502292B1 (de) * 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
CN101638440B (zh) * 2008-07-29 2011-10-26 中国人民解放军军事医学科学院基础医学研究所 一种可诱发机体抗肿瘤免疫的异种抗原-Fc融合蛋白及其应用
BR112021006941A2 (pt) * 2018-10-19 2021-08-31 The Francis Crick Institute Limited Antígenos de câncer inovadores e métodos
MX2021015765A (es) * 2019-06-28 2022-01-27 The Francis Crick Institute Ltd Nuevos antigenos y metodos contra el cancer.
AU2020309202A1 (en) * 2019-07-05 2021-12-09 Enara Bio Limited Novel cancer antigens and methods

Similar Documents

Publication Publication Date Title
JP2023162283A5 (enExample)
JP2023522198A5 (enExample)
ES2983085T3 (es) Fusión que comprende un péptido de penetración celular, un multiepítopo y un agonista peptídico de TLR para el tratamiento de cáncer
US10239916B2 (en) Controlled modulation of amino acid side chain length of peptide antigens
JP2023513720A5 (enExample)
ES2398492T3 (es) Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
JP2018510215A5 (enExample)
US20250312428A1 (en) Heterologous Prime Boost Vaccine
JP2023542297A5 (enExample)
JPS63500591A (ja) プラスモディウム　ビバックス　スポロゾイド外被タンパク質に相当する免疫原性ペプチド抗原
JP7686302B2 (ja) 融合遺伝子、組換え新型コロナウイルス高効率免疫ｄｎａワクチン、それらの構築方法及び使用
CN104755619A (zh) 用于预防猪水肿病的疫苗
US20260014250A1 (en) Immunoconjugate
Lee et al. Attachment of flagellin enhances the immunostimulatory activity of a hemagglutinin-ferritin nano-cage
EP2442825B1 (en) Method for the purification of protein complexes
CA2932211C (en) Antigen chimera, antigen composition, vaccine, method of preparing the same and cassette thereof
JP2022501046A (ja) アルギナーゼ１ポリペプチド
CN1404527A (zh) Tlp肽以及编码它们的dna序列
US11744901B2 (en) Phage conjugates and uses thereof
WO2005091753A2 (en) Flexible vaccine assembly and vaccine delivery platform
US20060204514A1 (en) Expression of hydrophobic proteins
JP2023522193A5 (enExample)
CN117177766A (zh) 疫苗平台
Nimal et al. Fusion of antigen to Fas-ligand in a DNA vaccine enhances immunogenicity
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier